ClinicalTrials.gg
RecruitingNCT05939167Updated Aug 12, 2025

Mesenchymal Stem Cells Treatment for AIDS Patients at Late Stage

A Phase 1/2 interventional study of mesenchymal stem cell and saline in AIDS, sponsored by Cell Energy Life Sciences Group Co. LTD. Recruiting at 4 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-08-12.

Sponsored by Cell Energy Life Sciences Group Co. LTD · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2023; still recruiting 2 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 87 studies in Acquired Immunodeficiency Syndrome with a site in China — 22 open to participants now, 24 under way, none of them phase 3. Acquired Immunodeficiency Syndrome · China.

Planned enrollment
29th of 68
150 · median 108
Started
2023
with 7 others
Phase 1/2
9 of 87
4 open now
Primary completion
2027-07
later than 17 of 23 live
Registered
66th of 87
by date

Among the 87 studies in Acquired Immunodeficiency Syndrome with a site in China, this one is the 29th largest by planned enrollment of the 68 interventional ones that give a count, is one of 8 that started in 2023, is one of 9 in phase 1/2, reaches primary completion later than 17 of the 23 other live ones, and was the 66th registered.

Acquired Immunodeficiency Syndrome

3,038 studies on the registry are indexed under Acquired Immunodeficiency Syndrome; 307 are open to participants now.

Browse Acquired Immunodeficiency Syndrome studies →

Open to participants now

22 of the 87 studies in Acquired Immunodeficiency Syndrome with a site in China are open now. Recruiting first, the newest first:

16 more — sign in →

All 22 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 198 Acquired Immunodeficiency Syndrome studies recruiting now, 118 (60%) set no upper age limit and 67 (34%) stop at 75 or younger; 43 take children under 18; 68 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 87 studies in Acquired Immunodeficiency Syndrome with a site in China, or all of them as a file.
02

Study summary

The goal of this study is to conduct a prospective, double-blind, randomized placebo-controlled clinical trial to investigate the safety and efficacy of mesenchymal stem cells treatment for AIDS patients at late stage.

Read the detailed description

Mesenchymal stem cells (MSCs) possess immunomodulatory, anti-inflammatory, and regenerative properties. The safety and effectiveness of MSCs have been investigated in various clinical trials for the treatment of several disorders, including graft-versushost disease, inflammatory bowel disease, and multiple sclerosis. It has been reported that MSC treatment in HIV-infected patients with immunological nonresponders resulted in a significant increase in circulating CD4+ T lymphocytes and a decrease of the activation of T lymphocytes and soluble inflammation mediator levels without significant adverse effects or loss of viremia control. However, the therapeutic efficacy of MSC treatment for AIDS patients at late stage is not well-understood. This study aims to investigate the safety and efficacy of MSC treatment for AIDS patients at late stage.

03

Conditions studied

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Confirmed infection, aged 18-65, both genders
  2. CD4+T count less than 500 cells/ul at baseline.
  3. No serious AIDS related events. 3. could understand and sign the form and comply with the requirements of this study.

4. agree not to participate in other studies and not to receive other immunotherapies during the period of participation in this study

Exclusion criteria

Exclusion Criteria:

  1. have //HDV/HEV infection, and the virological test is positive.
  2. The viral load for CMV and EBV is more than 1000 copies/ML.
  3. have -2 infection.
  4. have serious complications in organs including renal, circulatory, respiratory, digestive, endocrine, neural and immunological diseases and tumors.
  5. received treatment of hormones or other drugs for a long time.
  6. with serious AIDS related or unrelated events.
  7. received immunosuppressive drugs or systemic cytotoxic drugs for more than 3 months before recruiting
  8. have poor compliance during treatment.
  9. drug addiction within 6 months, or the urine drug test is positive
  10. participate in other clinical trials currently
  11. pregnant, breastfeeding, or have fertility requirements.
  12. unable or unwilling to provide informed consents, or unable to comply with research requirements.
  13. Other serious situations that may hinder clinical trials.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
150 participants (estimated)

Study arms

  • Placebo comparator
    placebo control

    use saline

    Other: saline

  • Experimental
    mesenchymal stem cells standard treatment

    transplant mesenchymal stem cells for 3 times

    Drug: mesenchymal stem cell

  • Experimental
    mesenchymal stem cells enhanced treatment

    transplant mesenchymal stem cells for 6 times

Interventions

  • Mesenchymal stem cell dose is 0.75-1.0×10\*6/kg and is transplanted by intravenous infusion. For the mesenchymal stem cell standard treatment group, the cells are used for three times(at week 0, 2,4 after recruitment) and the mesenchymal stem cell enhanced treatment group, the cells are used for six times(at week 0, 2,4,24,26,28 after recruitment).

    Also known as: umbilical cord derived MSCs

  • Othersaline

    saline is used as placebo in the placebo comparator group

06

What researchers measure

Primary outcomes

  1. Number of participants with side effects in MSCs treatment groups

    Investiagte the number of participants with treatment-related adverse events as assessed by CTCAE v4.0 after MSCs infusion.

    Time frame: 48 weeks

  2. CD4+ T cell counts after MSCs transfusion

    at week 12, 24 and 48, evaluate CD4+ T cell counts and compare with baseline

    Time frame: 48 weeks

Secondary outcomes

  1. HIV RNA viral load

    At week 12, 24 and 48, test HIV RNA viral load in participants' blood using RT-PCR and compare with baseline.

    Time frame: 48 weeks

07

Study locations

4 of 4 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2023 (actual). Primary completion is estimated for Jul 2027, 43 months after the start.

Of 29 phase 1/2 interventional studies under Acquired Immunodeficiency Syndrome, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 24. This study's planned 43 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2023
First posted
Jul 11, 2023
StartActual
Dec 10, 2023
Primary completionEst.
Jul 10, 2027
CompletionEst.
Jul 10, 2028
Last update
Aug 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05939167
Lead sponsor
Cell Energy Life Sciences Group Co. LTD
Collaborators
Beijing 302 Hospital, Shenzhen Third People's Hospital, Fifth Hospital of Shijiazhuang City, Beijing YouAn Hospital
Responsible party
Sponsor
First posted
Jul 11, 2023
Start date
Dec 10, 2023
Primary completion
Jul 10, 2027 (estimated)
Completion
Jul 10, 2028 (estimated)
Last update
Aug 12, 2025

Study contacts

Fu-Sheng Wang, Doctor
Contact
fswang302@163.com
8610-13671005510
Robert Chunhua Zhao, Doctor
Contact
zhaochunhua@vip.163.com
8610-13701289612
Fu-Sheng Wang, Doctor
principal investigator · Beijing 302 Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mesenchymal Stem Cell

Start the discussion